Keros Therapeutics, Inc. (KROS)

Keros Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	4.21	-187.35	-152.99	-104.68	-58.74	-45.36
Depreciation & Amortization	1.3	1.23	0.82	0.67	0.38	0.28
Loss (Gain) From Sale of Assets	-	-	0	0.01	0.05	-
Stock-Based Compensation	35.67	34.87	28.76	18.68	11.72	4.1
Other Operating Activities	2.07	1.82	1.55	0.94	0.52	1.82
Change in Accounts Receivable	-17.07	-2.6	-0.14	18	-18	-
Change in Accounts Payable	1.75	-0.25	1.61	-0.41	1.49	0.06
Change in Unearned Revenue	3.31	-	-	-	-	-
Change in Other Net Operating Assets	13.63	-8.59	-4.12	-3.28	0.45	2.21
Operating Cash Flow	44.86	-160.87	-124.51	-70.06	-62.15	-36.89
Capital Expenditures	-1.55	-1.93	-2.46	-1.24	-1.02	-0.29
Investing Cash Flow	-1.55	-1.93	-2.46	-1.24	-1.02	-0.29
Issuance of Common Stock	235.22	392.28	179.05	120.4	28.55	259.94
Other Financing Activities	-0.2	-0.45	-0.09	-0.09	-	-19.89
Financing Cash Flow	235.02	391.82	178.96	120.31	28.55	296.04
Net Cash Flow	278.34	229.02	51.98	49.01	-34.62	258.86
Free Cash Flow	43.31	-162.8	-126.97	-71.3	-63.17	-37.19
Free Cash Flow Margin	20.17%	-4585.91%	-84087.42%	-	-314.29%	-
Free Cash Flow Per Share	1.12	-4.35	-4.31	-2.83	-2.71	-2.40
Levered Free Cash Flow	30.29	-108.31	-81.25	-33.84	-39.48	-22.38
Unlevered Free Cash Flow	30.29	-108.31	-81.25	-33.84	-39.48	-22.37
Change in Net Working Capital	-1.32	10.71	2.15	-19.79	15.33	-2.71

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q